- Paradigm Array Labs New Offering is Launched at
Drug Discovery Technology Conference in Boston -
RESEARCH TRIANGLE PARK, N.C., Aug. 11 /PRNewswire-FirstCall/ -- Paradigm
Genetics, Inc. (Nasdaq: PDGM) and Arcturus Biosciences announced today the
establishment of a collaboration in which Paradigm Genetics' Paradigm Array
Laboratories has begun offering services using Arcturus' Laser Capture
Microdissection (LCM) systems and the Paradise Reagent System. Laser
dissection of tissue samples allows researchers to target specific cell types
for analysis, rather than mixed cell populations, resulting in more precise
genomic data. Gene expression within dissected samples is analyzed using
either Affymetrix or Agilent arrays. Paradigm Array Laboratories is the only
authorized service provider for both platforms.
Paradigm has launched access to their new LCM system-based services at the
Drug Discovery Technology conference, which is taking place August 8 -13 in
Boston, MA.
"This agreement with Paradigm provides Arcturus with an important new
channel for marketing the capabilities of our integrated microgenomics LCM
system and reagents that enable molecular analysis of microscopic tissue
samples. The Paradise Reagent System enables the measurement of whole genome
expression from both frozen and formalin-fixed, paraffin-embedded (FFPE)
tissue samples. This technology now allows genomic analysis of the wealth of
FFPE samples that have been archived in hospital settings, as well as from
clinical trials and basic research studies," stated Bob Schueren, EVP & COO of
Arcturus. "Paradigm is a recognized leader in systems biology and we are
pleased to work together co-promoting the services provided by the use of our
microgenomics platform."
"We have already secured a large pharmaceutical company as a new customer
for this service and are confident that we can continue this type of
commercial success. Establishing this collaboration with Arcturus expands
Paradigm's systems biology offering and provides scientists with more precise
tools for measuring changes at the microscopic cellular level that are
indicative of specific disease and drug activity. The LCM system and
integrated reagents are already in production as part of our systems biology
platform and are being used efficiently with both Affymetrix and Agilent
microarrays," said Thomas J. Colatsky, Ph.D., Vice President of Human Health
Research at Paradigm.
About Arcturus Bioscience
Arcturus Bioscience, Inc. is the leading company in laser microdissection
instruments and reagents for the analysis of microscopic tissue samples. These
tools enable researchers to perform rapid cell-based analysis of disease
progression utilizing the smallest and purest samples possible to date. The
company has developed this unique technology platform for genetic analysis of
biopsy samples and has applied its platform to discover cell-specific gene
signatures associated with human diseases such as cancer. Arcturus is a
private company headquartered in Mountain View, California.
About Paradigm Genetics
Paradigm Genetics is a biotechnology company applying its proprietary
systems biology platform to the discovery of safer, more effective drugs and
agrochemicals. Paradigm Genetics has major collaborations with the National
Institute of Environmental Health Sciences, Bayer CropScience, the Monsanto
Company, Pioneer Hi-Bred International, the National Institute of Standards &
Technology's Advanced Technology Program, and L'Oreal Inc. For more
information, visit http://www.ParadigmGenetics.com .
Safe Harbor Statement
This press release contains forward-looking statements, including
statements regarding the Company's expectations for using its systems biology
platform to discover biomarkers and inaccessible targets for small molecule
discovery. Such forward-looking statements are based on management's current
expectations and are subject to a number of risks, factors and uncertainties
that may cause actual results, events and performance to differ materially
from those referred to in the forward-looking statements. These risks, factors
and uncertainties include, but are not limited to, Paradigm's early stage of
development, history of net losses, technological and product development
uncertainties, reliance on research collaborations, uncertainty of additional
funding and ability to protect its patents and proprietary rights. Certain of
these and other risks are identified in Paradigm's annual report on Form 10-K
for the year ended December 31, 2003 and in its quarterly report on Form 10-Q
for the quarter ended March 31, 2004, each filed with the Securities and
Exchange Commission. The Company does not intend to update any of the forward-
looking statements after the date of this release to conform these statements
to actual results or to changes in our expectations, except as may be required
by law.
SOURCE Paradigm Genetics, Inc.
 back to top
Related links:
http://www.ParadigmGenetics.com
CONTACT:
Brian Ritchie or Mark Vincent of EURO RSCG
Life NRP, +1-212-845-4200
|
